SPOTLIGHT -
To BD or Not to Diagnose BD: That's the Question
What are some key considerations in diagnosing bipolar disorder? Joseph F. Goldberg, MD, shares insights at the recent 2023 Annual Psychiatric Times World CME Conference.
Getting Started With Buprenorphine
An expert addresses some common concerns about the drug and some effective ways clinicians can initiate the treatment at the 2023 Annual Psychiatric Times™ World CME Conference.
Beyond Benzos: Treatment Options for Insomnia
What are the treatment options for insomnia when avoiding benzodiazepines? John W. Winkelman MD, PhD, shares insights and guidance at the 2023 Annual Psychiatric Times World CME Conference.
“Clozapine Keeps Patients Alive”: Starting This Antipsychotic Sooner
Here’s why you should initiate clozapine sooner in patients with treatment-resistant schizophrenia.
A Practical Guide to Eliciting Positive Change in Patients Through Motivational Interviewing
An expert discusses motivational interviewing at the 2023 Annual Psychiatric Times™ World CME Conference.
The Earlier, the Better: Long-Acting Injectable Antipsychotics for Managing Schizophrenia
Sanjai Rao, MD, shared best practices for utilizing long-acting injectable antipsychotics at the 2023 Psychiatric Times World CME Conference.
Deep Dive on Dementia at the 2023 Psychiatric Times World CME Conference
Don't miss the the 2023 Psychiatric Times World CME conference, where our Editor in Chief will present on the 14 different types of dementia!
Orexin: The New Kid on the Insomnia Block
The newest class of medications to treat insomnia have many advantages.
Updates on Schizophrenia at the 2023 Psychiatric Times World CME Conference
Don't miss updates on schizophrenia at our conference, beginning at 3:10PM EST!
Why You Should Attend the 2023 Psychiatric Times World CME Conference
Our Editor in Chief explains why you should attend our conference!
How Do Treatments for Bipolar Disorder and SUD Affect One Another?
An expert discusses the connections between the 2 highly comorbid diseases and some ways to effectively treat both diseases simultaneously.
Positive Top-Line Phase 3 Data on Novel ADHD Treatment, CTx-1301
New positive data for novel ADHD treatment.
EMPOWERing the Next Generation
An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.
Keeping Up With the Times
Have you registered for the 2023 Annual Psychiatric Times World CME Conference?
Paliperidone Palmitate for Schizophrenia: Research on New Innovative Treatment for Unmet Needs
Christoph Correll, MD, shares more on paliperidone palmitate 6-month for the treatment of schizophrenia.
Study Supports Long-Term Efficacy of Esketamine Nasal Spray in Patients With TRD
Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.
Anhedonia in Major Depressive Disorder: Understanding Patient Burden
The relationship of this key symptom of major depressive disorder and patient burden is not well understood. These two posters covered it.
Study Compares Work Productivity Loss, Cost Savings in Esketamine Nasal Spray vs Quetiapine Extended-Release for TRD
“Among employed adults with TRD, esketamine nasal spray treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine extended-release treatment.”
Paliperidone Palmitate as a Treatment for Schizophrenia
These 3 posters covered the efficacy and safety of paliperidone palmitate in patients with schizophrenia.
First Year International Resident Shares Thoughts on Psychiatry
A psychiatry resident from Mexico reflects on the field.
International Resident's Reflections After US Psychiatric Conference
Introspections from an international resident following a US conference shed light on issues in geriatric psychiatry and more.
New Research, Treatment Issues Featured at Annual Meeting
Did you miss our APA Annual Meeting coverage?
Decentralized Clinical Trials
COVID-19 inspired researchers to devise new approaches to clinical trials.
Annual Meeting Session Highlights the Importance of Building Trainee Communities
How can trainees build and foster communities?
The Importance of Enhancing EDI in Child & Adolescent Psychiatry Training
Poster at annual meeting highlighted the importance of equity, diversity, and inclusion (EDI) training in child and adolescent psychiatry.
Cultivating Diversity Highlighted in Annual Meeting Session
Session at annual meeting discussed the importance cultivating diversity.
Crying at the 2023 APA Annual Meeting
Mental health professionals should cry. Here's why.
Understanding and Managing Behavioral and Psychological Symptoms of Dementia
Recognition is the first and most important step to treating behavioral and psychological symptoms of dementia.
The Week in Review: May 22-26
From the new Surgeon General’s Advisory on Social Media and Youth Mental Health to our exclusive coverage of the 2023 APA Annual Meeting, here are highlights from the week in Psychiatric Times.
“I Know It When I See It”: Definitions of Treatment-Resistant Depression
Presenters at the 2023 APA Annual Meeting compared definitions of treatment-resistant depression.
